Selected article for: "acute respiratory syndrome and long additional"

Author: Crawford, Katharine H D; Dingens, Adam S; Eguia, Rachel; Wolf, Caitlin R; Wilcox, Naomi; Logue, Jennifer K; Shuey, Kiel; Casto, Amanda M; Fiala, Brooke; Wrenn, Samuel; Pettie, Deleah; King, Neil P; Greninger, Alexander L; Chu, Helen Y; Bloom, Jesse D
Title: Dynamics of Neutralizing Antibody Titers in the Months After Severe Acute Respiratory Syndrome Coronavirus 2 Infection.
  • Cord-id: bosazmlm
  • Document date: 2021_2_3
  • ID: bosazmlm
    Snippet: Most individuals infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) develop neutralizing antibodies that target the viral spike protein. In this study, we quantified how levels of these antibodies change in the months after SARS-CoV-2 infection by examining longitudinal samples collected approximately 30-152 days after symptom onset from a prospective cohort of 32 recovered individuals with asymptomatic, mild, or moderate-severe disease. Neutralizing antibody titers decli
    Document: Most individuals infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) develop neutralizing antibodies that target the viral spike protein. In this study, we quantified how levels of these antibodies change in the months after SARS-CoV-2 infection by examining longitudinal samples collected approximately 30-152 days after symptom onset from a prospective cohort of 32 recovered individuals with asymptomatic, mild, or moderate-severe disease. Neutralizing antibody titers declined an average of about 4-fold from 1 to 4 months after symptom onset. This decline in neutralizing antibody titers was accompanied by a decline in total antibodies capable of binding the viral spike protein or its receptor-binding domain. Importantly, our data are consistent with the expected early immune response to viral infection, where an initial peak in antibody levels is followed by a decline to a lower plateau. Additional studies of long-lived B cells and antibody titers over longer time frames are necessary to determine the durability of immunity to SARS-CoV-2.

    Search related documents:
    Co phrase search for related documents
    • abbott architect and longitudinal cohort: 1, 2, 3, 4
    • abbott architect and longitudinal cohort study: 1, 2
    • abbott architect assay and acute infection: 1, 2
    • abbott architect assay and longitudinal cohort: 1, 2
    • abbott architect assay and longitudinal cohort study: 1, 2
    • acute infection and longitudinal cohort: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16
    • acute infection and longitudinal cohort study: 1, 2, 3, 4, 5, 6, 7, 8
    • acute infection and luciferase activity: 1
    • acute infection and luciferase assay system: 1